PD-L1 immunotherapy

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

April, 2025

PD-L1 immunotherapy

Jun 12, 2024, 04:11 | Insight

Nivolumab and Chemotherapy as First-Line Treatment for Metastatic Gastric Cancer: Updated Analysis and the Impact of FGFR2

"Nivolumab in combination with chemotherapy is the standard first-line treatment for metastatic gastric cancer expressing…

May 16, 2024, 14:31 | Blog

Cesar Perez: During the ASCO 2024 Educational Session, we will discuss the plethora of novel agents for Head and Neck Cancer

Cesar Perez, Director of Drug Development at Lake Nona DDU of Florida Cancer Specialists and…

All: 2 Posts: 1 - 100

'

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

'

Highlights from ELCC 2025

'

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

'

Meet the New AACR Board of Directores for 2025-2028 Term

'

Do Artificial Sweeteners Cause Cancer? Myths and Facts

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023